No increased risk of fatal cardiovascular events for breast cancer patients on newer hormone therapy
Thursday, April 21, 2016 - 14:00
in Health & Medicine
The use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke, report investigators.